December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

39.40 -0.65 (-1.62%)
Streaming Delayed Price Updated: 3:46 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 ↗
The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated. 
Via Stocktwits
News headline image
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
From Vera Therapeutics
Via GlobeNewswire
News headline image
Here are the top movers in Monday's session. ↗
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With Vera Therapeutics Stock? ↗
Vera Therapeutics shares are trading lower by 4.7% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. 
Via Benzinga
News headline image
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Monday? ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data ↗
Vera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phase 3 trial data. 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch ↗
Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing. 
Via Benzinga
News headline image
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Could Blast Off This Quarter ↗
 
Via Benzinga
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.